Cargando…
Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England’s prescription data during the COVID-19 pandemic (January 2019 to October 2020)
BACKGROUND: Management of high blood pressure (BP) typically requires adherence to medication regimes. However, it is known that the COVID-19 pandemic both interrupted access to some routine prescriptions and changed some patient health behaviours. AIM: This study, therefore, retrospectively investi...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702971/ https://www.ncbi.nlm.nih.gov/pubmed/36420815 http://dx.doi.org/10.1177/17539447221137170 |
_version_ | 1784839762140463104 |
---|---|
author | Barrett, Ravina Hodgkinson, James |
author_facet | Barrett, Ravina Hodgkinson, James |
author_sort | Barrett, Ravina |
collection | PubMed |
description | BACKGROUND: Management of high blood pressure (BP) typically requires adherence to medication regimes. However, it is known that the COVID-19 pandemic both interrupted access to some routine prescriptions and changed some patient health behaviours. AIM: This study, therefore, retrospectively investigated prescription reimbursement of cardiovascular (CVD) medicines as a proxy measure for patient adherence and access to medicines during the pandemic. METHODS: A cohort study of all primary care patients in England prescribed CVD medicines. The exposure was to the global pandemic. Prescriptions were compared before and after the pandemic’s onset. Statistical variation was the outcome of interest. RESULTS: Descriptive statistics show changes to monthly prescriptions, with wide confidence intervals indicating varying underlying practice. Analysis of variance reveals statistically significant differences for bendroflumethiazide, potassium-sparing diuretics, nicorandil, ezetimibe, ivabradine, ranolazine, colesevelam and midodrine. After the pandemic began (March–October 2020), negative parameters are observed for ACE inhibitors, beta-blockers, calcium channel blockers, statins, antiplatelet, antithrombotics, ARBs, loop diuretics, doxazosin, bendroflumethiazide, nitrates and indapamide, indicating decelerating monthly prescription items (statistically significant declines of calcium channel blockers, antithrombotic, adrenoreceptor blockers and diuretics) of CVD medicines within the general population. Many data points are not statistically significant, but fluctuations remain clinically important for the large population of patients taking these medications. CONCLUSION: A concerning decline in uptake of CVD therapies for chronic heart disease was observed. Accessible screening and treatment alongside financial relief on prescription levies are needed. A video abstract is (4 min 51 s) available: https://bit.ly/39gvEHi |
format | Online Article Text |
id | pubmed-9702971 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-97029712022-11-28 Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England’s prescription data during the COVID-19 pandemic (January 2019 to October 2020) Barrett, Ravina Hodgkinson, James Ther Adv Cardiovasc Dis Original Research BACKGROUND: Management of high blood pressure (BP) typically requires adherence to medication regimes. However, it is known that the COVID-19 pandemic both interrupted access to some routine prescriptions and changed some patient health behaviours. AIM: This study, therefore, retrospectively investigated prescription reimbursement of cardiovascular (CVD) medicines as a proxy measure for patient adherence and access to medicines during the pandemic. METHODS: A cohort study of all primary care patients in England prescribed CVD medicines. The exposure was to the global pandemic. Prescriptions were compared before and after the pandemic’s onset. Statistical variation was the outcome of interest. RESULTS: Descriptive statistics show changes to monthly prescriptions, with wide confidence intervals indicating varying underlying practice. Analysis of variance reveals statistically significant differences for bendroflumethiazide, potassium-sparing diuretics, nicorandil, ezetimibe, ivabradine, ranolazine, colesevelam and midodrine. After the pandemic began (March–October 2020), negative parameters are observed for ACE inhibitors, beta-blockers, calcium channel blockers, statins, antiplatelet, antithrombotics, ARBs, loop diuretics, doxazosin, bendroflumethiazide, nitrates and indapamide, indicating decelerating monthly prescription items (statistically significant declines of calcium channel blockers, antithrombotic, adrenoreceptor blockers and diuretics) of CVD medicines within the general population. Many data points are not statistically significant, but fluctuations remain clinically important for the large population of patients taking these medications. CONCLUSION: A concerning decline in uptake of CVD therapies for chronic heart disease was observed. Accessible screening and treatment alongside financial relief on prescription levies are needed. A video abstract is (4 min 51 s) available: https://bit.ly/39gvEHi SAGE Publications 2022-11-24 /pmc/articles/PMC9702971/ /pubmed/36420815 http://dx.doi.org/10.1177/17539447221137170 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Barrett, Ravina Hodgkinson, James Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England’s prescription data during the COVID-19 pandemic (January 2019 to October 2020) |
title | Impact of the COVID-19 pandemic on cardiovascular heart disease
medication use: time-series analysis of England’s prescription data during the
COVID-19 pandemic (January 2019 to October 2020) |
title_full | Impact of the COVID-19 pandemic on cardiovascular heart disease
medication use: time-series analysis of England’s prescription data during the
COVID-19 pandemic (January 2019 to October 2020) |
title_fullStr | Impact of the COVID-19 pandemic on cardiovascular heart disease
medication use: time-series analysis of England’s prescription data during the
COVID-19 pandemic (January 2019 to October 2020) |
title_full_unstemmed | Impact of the COVID-19 pandemic on cardiovascular heart disease
medication use: time-series analysis of England’s prescription data during the
COVID-19 pandemic (January 2019 to October 2020) |
title_short | Impact of the COVID-19 pandemic on cardiovascular heart disease
medication use: time-series analysis of England’s prescription data during the
COVID-19 pandemic (January 2019 to October 2020) |
title_sort | impact of the covid-19 pandemic on cardiovascular heart disease
medication use: time-series analysis of england’s prescription data during the
covid-19 pandemic (january 2019 to october 2020) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702971/ https://www.ncbi.nlm.nih.gov/pubmed/36420815 http://dx.doi.org/10.1177/17539447221137170 |
work_keys_str_mv | AT barrettravina impactofthecovid19pandemiconcardiovascularheartdiseasemedicationusetimeseriesanalysisofenglandsprescriptiondataduringthecovid19pandemicjanuary2019tooctober2020 AT hodgkinsonjames impactofthecovid19pandemiconcardiovascularheartdiseasemedicationusetimeseriesanalysisofenglandsprescriptiondataduringthecovid19pandemicjanuary2019tooctober2020 |